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doi:10.1016/j.pedneo.2012.01.004Invasive fungal infections represent the third-leading cause of late-onset sepsis in very-low-
birth-weight infants (VLBWI) and have a high rate of infection-associated mortality. The infants
at high risk for fungal sepsis are VLBWI with presence of additional risk factors that contribute
to increased colonization and concentration of fungal organisms. Colonization with Candida
spp. in neonates is secondary to either maternal vertical transmission or nosocomial acquisi-
tion in the nursery. Multiple sites may become colonized and a direct correlation between
fungal colonization and subsequent progression to invasive candidemia was determined.
Randomized, single and multiple-center, placebo-controlled trials found intravenous flucona-
zole prophylaxis to be effective in decreasing fungal colonization and sepsis for at-risk preterm
infants <1500 g birth weight. The prophylactic use of fluconazole was found to be safe with no
significant development of fungal resistance. Fluconazole prophylaxis administered to preterm
neonates with birth weight <1000 g and/or 27 weeks’ gestation or less has the potential of
reducing and potentially eliminating invasive fungal infections and Candida-related mortality.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Invasive fungal infections (IFI) represent a leading cause of
sepsis in very-low-birth-weight (VLBW) infants and result in
high rates of morbidity and mortality.1e4 Among many riskpartment, Soroka University
va 84101, Israel.
.
an Pediatric Association. Publishfactors responsible for development of IFI, previous
mucosal and skin colonization are of primary importance.
Colonization with Candida in neonates is secondary to
either maternal transmission or to nosocomial acquisition in
the neonatal intensive care unit (NICU).5e7
Because current therapies for systemic fungal diseases
are not universally successful and morbidity remains high,
efforts may be better focused on preventing invasive
disease by interrupting the process of colonization and
subsequently preventing the development of serious fungaled by Elsevier Taiwan LLC. All rights reserved.
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nization patterns, timing, anatomic sites involved and
specific species distribution is important for both the
clinician and scientist. The preventive strategy using flu-
conazole for the prevention of colonization and systemic
infections with Candida spp. in both extremely low-birth-
weight (ELBW) and VLBW infants was found to be effec-
tive in several studies.8e11
We present in this review an up-to-date summary of the
information accumulated during recent years regarding the
epidemiology and risk factors for IFI in the neonatal pop-
ulation, concentrating on the presently available strategies
for decreasing fungal colonization, IFI and mortality in at-
risk preterm infants.2. Neonatal Invasive Fungal Infections
Invasive fungal infections (IFI) represent the third-leading
(12.2%) cause of late-onset sepsis in VLBW (birth weight
<1500 g) infants. Their estimated incidence is 1.6e3% in
VLBW infants and up to 15e20% in ELBW neonates with
a Candida-attributable mortality of 25e55% and presence
of associated neurodevelopmental impairment at 18 years
old in 57% of survivors.1,2,11,12 The incidence of IFI varies
considerably between reporting NICUs, being related,
mainly, to the number of ELBW infants <24e25 weeks of
age taken care at a specific NICU.1,2
Candida albicans is the most prevalent fungal pathogen
in neonatal disease, but the incidence of infection caused
by other Candida species, particularly Candida parapsilosis
and Candida glabrata has also increased dramatically
during the past two decades.3,4,13,14 Furthermore, C.
glabrata and Candida krusei, another increasingly recov-
ered representative of Candida spp., harbor innate resis-
tance to the azole class of antifungal agents and may
represent therapeutic challenges in IFI.
The highest incidence of IFI in VLBW infants is recorded
between the second and sixth weeks after birth. Neonatal
IFI are not confined to hematogenous sepsis, but may
involve the central nervous system (meningitis and brain
abscesses), urinary tract, soft and deep tissues, endo-
carditis, endophtalmitis, hepatitis and pneumonitis.15,16
While the clinical picture is similar to that of late-onset
Gram-negative bacterial infections, the blood cultures of
Candida spp. may be negative even in cases of deep-organ
involvement and confirmed Candida meningitis.12
Risk factors for IFI include prematurity, VLBW, use of
central venous lines, intubation, parenteral nutrition,
broad-spectrum antibiotics administration (in particular
third-generation cephalosporins), prolonged hospitaliza-
tion, abdominal surgery, exposure to an H2 blocker, and
colonization with Candida spp.12,17e19 Of these many
factors, mucosal and skin colonization are of primary
importance. In a single-center study enrolling 146 VLBW
infants, fungal colonization occurred in 26.7% and one-
third of those colonized developed IFI.5 In 1991e1992,
El-Mohandes20 studied 82 (61 infants <1500 g) consecutive
NICU admissions and found a colonization rate with
Candida spp. of 19% with stools more frequently culture-
positive than skin or gastric aspirates. Five of the study
patients developed fungal sepsis; the authors found thatgastrointestinal colonization was strongly associated with
development of C. parapsilosis sepsis. Rowen21 reported
that endotracheal colonization with Candida enhances risk
of systemic candidiasis in VLBW infants. Huang22 found
a colonization rate of 22% among 116 2-week-old VLBW
infants (rectal colonization present in 76% of colonized
infants) with fungemia developing in three infants;
however, in only one-third of infants could an association
between colonization and fungemia be found). Manzoni19
found colonization and IFI rates of 32.1% and 8.1%,
respectively, among the 689 VLBW infants admitted during
1998e2005 at an NICU in Torino, Italy. After logistic
regression, colonization of central venous catheters and
colonization in multiple sites were found to be independent
risk factors and predictors of progression to fungal sepsis.
Regarding the antifungal treatment of IFI, amphotericin
B deoxycholate, amphotericin B lipid preparations and
fluconazole are the most commonly used antifungal in
neonates with invasive infections, as well as in older
pediatric patients; however, the development of newer
generation azoles (voriconazole, posaconazole) and echi-
nocandins (mainly caspofungin), still undergoing extensive
study on dosing and safety, may ultimately expand the
therapeutic options for single-agent and combination
therapy for neonatal candidiasis.7,23e283. Neonatal Colonization with Candida spp.
Colonization with Candida spp. in neonates may be
secondary to either vertical transmission from the mother
or horizontal (nosocomial acquisition) transmission in the
nursery or NICU. Studies evaluating gastrointestinal colo-
nization have shown that 4.8e10% of neonates will harbor
a strain of Candida on admission to the nursery.26 At NICUs,
around 50% of the admitted infants may be colonized by the
end of the first week of life and up to 64% could be
colonized by 4 weeks old.5,29 The majority of infants are
colonized with C. albicans, but a large percentage carry C.
parapsilosis6,29 (a pattern different from that encountered
in adults). An increase in the incidence of C. parapsilosis
neonatal infections has been reported during the past two
decades in parallel to a decrease in the representation of C.
albicans strains among the fungal isolates recovered at
various NICUs.3,4,20
The Candida strains colonizing the infant are most
frequently acquired by transmission from the maternal
genitourinary or gastrointestinal tract during the perinatal
period. Using molecular typing techniques, vertical trans-
mission of C. albicans was documented in 33% of a group
of premature infants.29 While vertical transmission is
common, horizontal acquisition of Candida (from care
providers or contaminated infusions) does occur in the NICU
and is probably the most common mode of transmission for
C. parapsilosis.6,29 Candida spp. were isolated from the
hands of 29% (859 of 2989 sampled) of health workers in
a multicenter study.6,18 Candida parapsilosis was isolated
from 19% and C. albicans from 5% of the hand cultures of
the healthcare personnel sampled.
In a multicenter study of neonatal bloodstream infec-
tions with Candida spp., molecular typing demonstrated
that the same fungal strains were present in the bloodstream
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the relationship between gastrointestinal tract colonization
and development of IFI.17 In this study, infants >1000 g
were more likely to be colonized with C. albicans than C.
parapsilosis, while infants <1000 g showed no differences
between the rate of colonization of C. albicans versus C.
parapsilosis. The same study found by univariate analysis
that rectal colonization by fungi was a risk factor for can-
didemia. Recently, in a single-center study from Virginia,
USA, in which 50 high-risk VLBW infants were enrolled,
Candida was isolated from surveillance cultures in 31 (62%)
infants and the colonization was inversely proportional with
the gestational age. Fungal colonization of the skin and
gastrointestinal tract was reported to occur before that of
the respiratory tract and C. albicans was found more likely
than C. parapsilosis to colonize multiple sites.30 Ven-
detuolli et al31 obtained Candida surveillance cultures from
51 NICU patients during 2005e2007 and found that 16
infants (15 of them <27 weeks gestational age) with posi-
tive cultures developed subsequent IFI compared with the
34 others who did not have fungal colonization and did not
develop IFI. The positive surveillance cultures led to an
early initiation of antifungal treatment and only one infant
died of Candida infection.31
4. Prevention of Neonatal Fungal Colonization
and Invasive Disease
4.1. Fluconazole prophylaxis
Fluconazole is an azole with a long half-life, very good
cerebrospinal penetration, low protein binding and good
tissue, body fluids and mucocutaneous areas levels (higher
than plasma ones), characteristics that allow long dosing
intervals, excellent tissue penetration and easy elimina-
tion.32,33 At the present time, fluconazole is considered to
be the main alternative to amphotericin B in the treatment
of neonatal candidiasis and has been fairly well charac-
terized in this population.34,35
In VLBW infants, prevention of fungal colonization and
IFI by fluconazole prophylaxis has been shown to be
effective in 13 studies (nine retrospective and four
prospective randomized) during the past decade.36e48 The
four randomized, placebo-controlled studies completed
during 2000e2007 are presented in detail in Table 1.36e38,44
In 2001, Kicklighter et al and Kaufman et al reported the
first two randomized, double-blind, placebo-controlled
trials of administration of fluconazole prophylaxis in
extremely VLBW infants in order to prevent Candida colo-
nization and IFI.36,37 They used protocols which treated
(starting in the first 72 hours of life) VLBW infants with
a birth weight of <1500 g and 1000 g, respectively, with an
intravenous/oral or intravenous-only fluconazole dose of 3
or 6 mg/kg in different daily schedules till day 28e42.36,37
The authors reported significant decreases in Candida
colonization and IFI rates, without changes in the sensi-
tivities of the fungal isolates to fluconazole during the
study period and without documentation of adverse effects
of the fluconazole therapy. In 2005, Kaufman et al38
extended their previous study and administered flucona-
zole twice weekly (instead of daily treatment) at a dose of3 mg/kg/day and demonstrated equivalence between the
daily and twice-weekly dosages in respect of colonization
and IFI occurrence reductions between the two schedules.
A recent multicenter, prospective, randomized clinical
trial has added important data on the safety and efficacy
of this practice.44 Manzoni et al enrolled during 2004e2005
in Italy all neonates <1500 g at birth from eight tertiary
NICUs (322 infants) and randomly assigned them to receive
either fluconazole (intravenously or through an orogastric
tube, 3 or 6 mg/kg/day every third day for the first
2 weeks and then every day) or placebo from birth until
Day 30 of life (Day 45 for those <1000 g at birth). The
authors reported significant reductions in fungal coloniza-
tion and IFI for both treatment groups, but could not prove
an effect of the therapy on the relationship between
colonization and the subsequent development of IFI. The
overall mortality and the incidence of cholestasis were not
different between the treatment and placebo groups and
no evidence for emergence of resistant Candida spp. was
observed.44
Overall, 400 and 1522 evaluable VLBW neonates were
treated with various fluconazole prophylaxis regimes in the
four prospective randomized and the nine retrospective
studies mentioned, respectively. Summarizing all the
available data, fluconazole prophylaxis was found to reduce
IFI by >85% in all infants <1500 g and by 91% in high-risk
infants <1000 g. The all-cause mortality was 11% for the
fluconazole-treated group compared with 16.3% for
controls while nearly eliminating (96% reduction) Candi-
daerelated mortality, with no documentation of significant
adverse effects.8e10,23 In a recent study completed on
patients who were enrolled in the initial randomized,
controlled study on fluconazole prophylaxis of IFI per-
formed by Kaufmann et al, there were no long-term
adverse effects on neurodevelopmental parameters and
quality of life at 8e10 years old.494.2. Fluconazole resistance issues
The use of fluconazole prophylaxis in NICU raised concern
about the development of resistance, including possible
selection of Candida spp. with acquired resistance or of
natively fluconazole-resistant strains like C. glabrata and C.
krusei replacing fluconazole-susceptible species. Epidemi-
ologic data from 127 adult institutions in the USA showed
that the incidence of fluconazole-resistant Candida spp. is
rising, prompting concerns that that such resistance
patterns may soon develop in the neonatal population.50,51
In a pediatric study reporting on the antifungal suscepti-
bility of 179 clinical Candida spp. isolated from four chil-
dren’s hospitals in the USA (patient age not detailed),52
C. albicans, C. parapsilosis, C. glabrata, Candida tropica-
lis, Candida lusitaniae and C. krusei were identified from
43%, 32%, 8%, 8%, 8% and 1%, respectively. Fluconazole
resistance was recorded among C. glabrata, C. tropicalis
and C. krusei isolates (7%, 36% and 100%, respectively).
Among C. parapsilosis isolates, 18% were resistant to
amphotericin B. Caspofungin was the most active agent
in vitro against all Candida spp. (100% for all of them, with
the exception of C. parapsilosis where a 98% susceptibility
rate was reported).52
Table 1 Randomized, placebo-controlled studies on the efficacy of fluconazole prophylaxis on colonization with Candida spp. and on invasive fungal infections.
Study Study
characteristics
Enrollment criteria No. patients
enrolled









R, SC, PL-C All BW < 1500 g within
72 h of life
53-F
50-PL
IV 6 mg/kg every 72 h
DOL 7 and then every
24 h until DOL 28
C:15.1% vs. 46%
(p Z 0.0005)
No No 9.4% (F) vs. 20%





All BW < 1000 g 50-F
50-PL
IV 3 mg/kg/day every
third day for first 2 wks,
every other day for wks
3e4 and daily for wks
5e6
C: 22% vs. 60%
(p Z 0.002)
IFI: none vs. 20%
(p Z 0.008)




R, SC, DB All BW < 1000 g within




41 (A) - initial
protocol37
40 (B) - twice
a week
A: 3 mg/kg/d every 72 h
(Days 1e14), every 48 h
(Days 15e28), every 24 h
(Days 29e42)
B: 3 mg/kg/d twice
a week for 6 wks
C: 12% vs. 10% (p Z NS)
IFI: 5% vs. 3% (p Z NS)







All BW < 1500 g
admitted at




IV 6 or 3 mg/kg from
birth to Day 30*
C (6 mg/3 mg/PL): 9.8%/
7.7%/29.2%; p < 0.001
for 6 and 3 mg/kg vs. p
IFI: 2.7%/3.8%/13.2%;
p Z 0.005 (6 mg) and
0.02 (3 mg) vs. PL
No No 8%/8.7%/9.4%
(p Z NS)
BW Z birth weight; C Z colonization; DB Z double-blind; DOL Z day of life; F Z fluconazole; IFI Z invasive fungal infection; IV Z intravenous; MC Z multicenter; NICU Z neonatal
intensive care unit; PL Z placebo; PL-C Z placebo-controlled; R Z randomized; Rx Z treatment; SC Z single center.
* Day 45 for BW < 1000 g.
y Serum transaminases elevated in three patients in each group.
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been observed in five major neonatal prophylaxis
studies36e38,41,44 where surveillance cultures for coloniza-
tion (at baseline and weekly during the study period) were
performed. There was no significant increase in minimum
inhibitory concentration to fluconazole of the fungal isolates
during the prophylaxis period (between 4 and 6 weeks) or
the entire study period (2e3 years). Furthermore, there was
no emergence or increase in the incidence of colonization or
infection from C. glabrata or C. krusei reported in any
studies, including a recent single-center analysis of 10
years.46,53 However, there is general agreement that even
targeted fluconazole prophylaxis in neonates will still drive
the emergence of azole resistance.54 The follow-up periods
(up to 30 months) are probably insufficient to detect clini-
cally significant changes in the resistance profile of fungal
isolates. Antifungal prophylaxis may take years after the
introduction of fluconazole prophylaxis to become estab-
lished in NICUs.55 Sarvikiki et al55 recently describes their
experience with fluconazole prophylaxis over a 12-year
period; they reported no C. glabrata or C. krusei-IFI and
only two cases of resistant C. parapsilosis-IFI. It was inter-
esting to remark that when fluconazole prophylaxis was
administered daily at 6e12 mg/kg/kg in infants<1000 g and
<30 weeks gestational age between 1991e2000, no fungal
resistance was detected. However, when the use of fluco-
nazole was broadened to the entire NICU in 2000, the
emergence of resistance was noted in two patients who
were infected with an endemic strain that had previously
been susceptible.55 In a case report from 2007, a premature
infant with persistent C. albicans candidemia was success-
fully treated with caspofungin after the isolate developed
resistance to fluconazole and voriconazole during the initial
treatment with fluconazole.26
4.3. Nystatin prophylaxis
Oral nystatin was the first antifungal drug studied for the
prophylaxis of IFI in preterm infants. Previous small studies
demonstrated a significant reduction in fungal bloodstream
infection or meningitis when the prophylaxis was adminis-
tered early after birth.56e59 One recent randomized,
controlled trial compared oral fluconazole to nystatin
prophylaxis initiated during the first 7 days of life in VLWB
infants <1500 g.60 IFI were diagnosed in 2.35 (5.3%) of the
fluconazole-treated premature infants compared with 6/42
(14.3%) of the nystatin-treated infants. There was no
mortality in the fluconazole-treated patients compared
with 6/42 (7.5%) in the nystatin-treated infants (pZ 0.03),
when the majority of fatalities were caused by bowel
perforation and necrotizing enterocolitis. In fact, good
safety data are lacking for the use of nystatin in neonates;
in addition, the drug can be administered only enterally
(and therefore not in patients with necrotizing enterocolitis
or other gastrointestinal pathologies) and, subsequently,
will affect only the gastrointestinal fungal colonization.9,10
4.4. Present recommendations
According to the available findings, it is accepted today
that the decisions regarding fluconazole prophylaxis shouldbe made according to its effect on the colonization and IFI
incidence, mortality and neurodevelopmental impairment
following IFI. Individual NICUs have to examine their inci-
dence, neurodevelopmental impairment outcomes and
mortality with IFI by various gestational ages and decide on
their standard prophylaxis practices.
Criticism and concern regarding the routine use of flu-
conazole in NICUs is related, mainly, to the lack of satis-
factory data about the true burden of IFI in preterm
infants, leading to a wide range of incidence rates, with
many NICUs reporting rates of 2e3% or less, which, theo-
retically, would not justify the use of fluconazole. In fact,
most of the studies showing the efficacy of fluconazole
prophylaxis were published from centers having high rates
of IFI.36e38,41,44 Many studies report only on the rates of
bloodstream infections and data on specific local antibiotic
use and feeding practices, antifungal prophylaxis policies
with drugs other than fluconazole (mostly nystatin), infec-
tion control measures adopted, resuscitation practices or
numbers of patients admitted with complicated abdominal
surgery procedures are incomplete. Additional concerns are
related, of course, to the effects of widespread use of
fluconazole particularly on specific Candida subspecies like
C. glabrata and C. krusei (and even C. parapsilosis) known
to have intrinsic resistance to this drug. Therefore, future
studies will have to provide additional information on some
unsolved issues like the effect of fluconazole on overall
mortality, efficacy of prophylaxis for shorter periods of
time (like during the antibiotic therapy only), possible liver
toxic effects, interaction with other drugs and identifica-
tion of premature infant subpopulations with the most
beneficial outcome, while continuously and carefully
monitoring the possible development of resistance with the
broad use of the drug.
Meanwhile, the most beneficial approach seems to be by
targeting fluconazole prophylaxis to all infants <1000 g or
27 weeks gestational age admitted at NICUs with
moderate-to-high rates of IFI (5e10%, for example) while
they require intravenous access, starting on Day 1 of life
and continuing till 6 weeks of life. This approach was found,
in the USA, to prevent 2000e3000 IFI, 200e400 Candida-
related deaths and 900e1200 infants developing neuro-
developmental impairment (of a total of 30,000 preterm
infants <1000 g or 27 weeks’ gestation born each year).9
The infants with a birth weight of 1000e1500 g may also be
candidates for such an approach or a more targeted one
(using prophylaxis only from those with central venous
catheters or those receiving antibiotics and as a function of
the overall IFI rates at the specific NICU).
How are such recommendations accepted and imple-
mented? In a European survey on the prophylactic use of
fluconazole in NICUs, 193 structured questionnaires on the
practice of fluconazole prophylaxis, completed by 223
neonatologists from 28 countries, were analyzed.61 Use of
prophylaxis was reported by 55% of the interviewed
neonatologists, while fluconazole represented the most
commonly used prophylactic agent (92%). The dose most
commonly used was 3 mg/kg/day (88% of the physicians
using the drug) with an administration interval of 72 hours
in 52% of them. The decision not to use prophylaxis was
mainly based on local data on the incidence of IFI, concern
about the possible increase in antifungal resistance and
88 E. Leibovitzlack of specific guidelines by the pediatric and neonatology
societies.615. Conclusions
Fluconazole prophylaxis was shown, in carefully performed,
randomized, placebo-controlled studies, to reduce Candida
spp. colonization and IFI rates without emergence of drug
resistance and without adverse effects during extended
periods of time. Fluconazole prophylaxis administered to
preterm neonates with birth weight <1000 g and/or 27
weeks’ gestation or less has the potential of reducing and
potentially eliminating IFI and Candida-related mortality.References
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